WHY IS PULSE-8™ GOOD FOR ME?

Taking additional measures toward maintaining cardiovascular health is becoming increasingly critical in the pursuit of living a long, happy life. Today, cardiovascular disease is the number one cause of death and claims more lives than all cancers combined. It affects 17.5 million people and includes symptoms like chest pain, high blood pressure, shortness of breath, fatigue, swollen legs, rapid heart rate, arrhythmia, stroke and heart attack.

Adding Pulse-8™ to your daily health routine is the perfect first step toward creating a healthier heart. Pulse-8 features L-arginine, which is known to support optimal cardiovascular health. Some of the amazing benefits of Pulse-8™ with L-Arginine include improved energy, enhanced immune system function, healthy male sexual performance, improved mood and overall sense of wellbeing.

INGREDIENT HIGHLIGHTS

The Key to Cardiovascular Health

L-arginine — an amino acid that plays a vital role in multiple physiological functions in the body, but is best known for its cardiovascular benefits. In the body, L-arginine converts to nitric oxide. Nitric oxide is a powerful neurotransmitter that aids in the relaxation of blood vessels and helps improve circulation and regulate vessel tone and flexibility. These effects support increased blood flow, which in turn increases endurance, reduces stress on the heart, improves circulation, and helps to maintain blood pressure levels already within a normal range.

CoQ10 — A molecule produced in the body which helps the mitochondria produce energy. Heart attacks and fibromyalgia are among the diseases associated with low levels of CoQ10. Important in reducing plaque buildup in the arteries.

L-Citrulline — An amino acid which has been proven to reduce fatigue and improve endurance for both aerobic and anaerobic prolonged exercise. Has also been used to alleviate erectile dysfunction caused by high blood pressure.

D-Ribose — Contributes to the formation of DNA and RNA. D-Ribose has been used to treat Chronic Fatigue Syndrome, Fibromyalgia and heart failure.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

30 SERVINGS PER CANISTER

Directions: Mix one scoop of Pulse-8™ with 4-8 ounces of water to taste. Stir to dissolve. If water is very cold, mixture may take longer to dissolve. Pulse-8 may be taken once daily.

Before starting a new dietary or exercise program, consult your healthcare provider. If you are pregnant, nursing, have a known medical condition or are taking any medications, it is recommended to consult your healthcare provider before taking this product.

Store in a cool, dry place. Keep out of reach of children.

HYPOTHESES OF THE EFFECTS OF L-ARGININE AND NITRIC OXIDE ON THE BODY:

By Dr. Adam Saucedo

Disclaimer and comments on the following work. The authors of the work cannot be held responsible for any statements made by others as a result of this work. What follows are HYPOTHESES of effects of l-arginine based on the literature that follows. Some effects have more data to substantiate the hypothesis than others. None of the hypothesized effects can be taken as fact, by definition. Read the following references and base your conclusion on these readings and as many other sources of research in the literature that you are able to study.

Hypothesized Effects of L-arginine:

• Decreasing and Reversing Atherosclerosis by decreasing intimal thickening and monocyte accumulation 9,10,11,12,13,14
• Restore normal endothelial function in hypercholesterolemia 14,15,16,17,18,19,20,21
• Reversing consequences of Coronary Artery Disease 22,23,24,25,26,27,28,29,30
• Decreasing cholesterol and triglycerides 32
• Improves walking distance in Peripheral Vascular Disease 31,33,34,35,36
• Improves pain in Interstitial Cystitis 37,38
• Prolonged administration of Arginine reverses adverse effects of High Blood Pressure 39,40,41,42
• Decreases High Blood Pressure 43
• Decreases post operative infection and length of stay 44
• Increases Human Growth Hormone 45,46,47,48,49,50,116
• Improves outcome after Bypass Surgery 51
• Improves sexual function 52
• Improves exercise tolerance 53,54
• Improves renal function 55,56,57,58,59,60
• Improves glucose uptake in muscle cells 61
• Improves Asthma 61,62,63,64,65,66
• Improves cell mediated immunity 67,68,69,70,71
• Improves pituitary responsiveness and Modulates Hormonal Control 72,73,74
• Improves muscle performance 75
• Improves Diabetes and reverses Damage 76,77,78,79
• May prevent Diabetes 78
• Reduces blood clots and strokes 80,81,82
• Helps prevent restenosis after Angioplasty and bypass 83,84,85
• Helps prevent post surgical damage after intestinal manipulation 86
• May improve Irritable Bowel Syndrome 87
• Improves osteoporosis 88
• May improve prostate function 89
• May give protection against size of Heart Attack 90
• Helps protect in cardiac transplants 91,92
• Improve Scleroderma 93
• Improve Sickle Cell Disease 94
• Prevent Pre-eclampsia 95
• Improves exercise capacity in Pulmonary Hypertension 96,117,118
• Improves healing 97,98,99
• Reduces Ulcers 101,102
• Improves Peripheral Vascular Disease 103,104
• Improves outcome in Sepsis 105
• Improves Heart Failure 106
• Improves outcome of Cancer Treatment 107,108
• Improve Alzheimer’s 109,110,111,112
• Improves memory and cognitive functions 113,114,115
• L-Arginine has been shown to safe in the above studies as well as others 100,116

References

1. Fried R, Merrell WC. The Arginine Solution. New York, NY. Warner Books, 1999.
2. Coffee, C J: Metabolism. Madison, Ct: Fence Creek Publishing, 1998.pp388-389
3. Catt KJ: Molecular Mechanisms of Hormone Action. In Endocrinology and Metabolism, 3rd ed. Edited by Felig P, Baxter JD, Frohman LA. New York, NY: McGraw-Hill, 1995, pp 138-139
4. Gerhard M, et al. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996 Apr;27(4):849-53
5. Toprakci M, et al. Age-associated changes in nitric oxide metabolites, nitrite and nitrate. Int J Clin Lab Res 2000;30(2):83-5
6. Sakuma I, et al. Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988 Nov;85(22):8664-7
7. Vallance P, Moncada S. Nitric Oxide—from mediator to medicines. J R Coll Physicians Lond 1994 May-Jun;28 (3): 209-219
8. Kam PC, Govender G. Nitric oxide: basic science and clinical applications. Anaesthesia 1994 Jun;49(6): 515-21
9. Sinha G. Viagra: ups and downs. Popular Science 2000 July: page 35
10. Boger RH, Bode-Boger SM, Kienke S, et al. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits.Atherosclerosis 1998 Jan;136(1) 67-77
11. Cheng JW, Balwin SN. L-Arginine in the management of cardiovascular diseases. Ann Pharmacother 2001 Jun;35(6):755-64
12. Tentolouris C, Tousoulis D, et al. L-Arginine in coronary atherosclerosis. Int J Cardiol 2000 Sep 15;75(2-3):123-8
13. Wang B, Ho HV, et al. Regression of atherosclerosis. Circulation 1999;99(9):1236-41
14. Boger RH, Bode-Boger SM, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol fed rabbits: comparison with lovastatin. Circulation 1997; 96(4):1282-90
15. Schuschke DA, Miller FN, Lominadze DG, Feldhoff RC. L-arginine restores cholesterol-attenuated micro vascular responses in the rat cremaster. Int J Micricirc Clin Exp 1994 Jul-Aug;14(4): 204-11
16. Orlandi A, Marcellini M Spagnoli LG. Aging influences development and progression of early aortic atherosclerosis lesions in cholesterol-fed rabbits. Arterioscler Thromb Vasac Biol 2000 Apr;20
17. Chong PH, Bachenheimer BS. Current, New and future treatments in dyslipidemia and atherosclerosis. Drugs 2000 Jul;60(1):55-93
18. . Phivthong-ngam L, Bode-Boger SM, Boger RH, et al. Dietary L-arginine normalizes endothelial induced vascular contractions in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1998 Aug;32(2): 300-7
19. Maxwell AJ, Anderson B Zapien MP, Cooke JP. Endothelial dysfunction in hypercholesterolemia is reversed by: nutritional product designed to enhance nitric oxide activity.Cardiovasc Drugs Ther 2000 Jun;14(3):309-16
20. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelial- dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996 April; 97(8): 1989-94
21. . Cooke JP, Dzau J, Creager A. Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. Basic Res Cardiol 1991; 86 Suppl 2: 173-81
22. Fraser GE. Diet and coronary heart disease: beyond dietary fats and low-density- lipoprotein cholesterol. Am J Clin Nutr 1994 May;59(5 Suppl) 1117s-1142sand atherosclerosis. Drugs 2000 Jul;60(1):55-93
23. Quyyumi AA. Does acute improvement of endothelial dysfunction in coronary arterydisease improve myocardial ischemia? J Am Coll Cardiol 1998 Oct;32(4):904-11
24. Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine supplementation improves small vessel coronary endothelial function in humans. Circulation 1998 Jun 2;97(21):1648-9
25. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997 Aug 1; 80(3):331-3
26. Desrois M, Sciaky M, Lan C, et al. L-arginine during long-term ischemia: effects on cardiac function, energetic metabolism and endothelial damage. J Heart Lung Transplant 2000 April; 19(4): 367-76
27. Quyyumi AA, Dakak N, Dodati JG, et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation, J AM Coll Cardiol 1997 Nov 1; 30(5):1220-7
28. Egashira K, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996;94(2):130-4
29. Tentoluris C, et al. L-arginine in coronary atherosclerosis. Int J Cardiol 2000 Sep15;75(2-3):123-8
30. Tretjakovs P, Kalnins U, Dabina I, et al. Plasma HDL-cholesterol has an effect on nitric oxide production and arachidonic production in the platelet membranes of coronary artery disease patients without LDL-hypercholesterolemia. Med Sci Monitor 2000 May- Jun;6(3):507-11
31. Bode-Boger SM, Boger RH, Galland A, Tsikas D Frolich JC. L-arginine induced vasodilatation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 1998 Nov; 46(5): 489-97
32. Khedara A, Kawai Y Kayashita J Kato N. Feeding rats the nitric oxide synthase inhibitor, L-N(omega) nitroarginine, elevates serum triglycerides and cholesterol and lowers hepatic fatty acid oxidation. J Nutr 1996 Oct;126(10):2563-7
33. Boger RH, Bode-Boger SM, Theil W, et al. Restoring vascular nitric oxide formation by L-arginine improves symptoms of intermittent claudication in patients with Peripheral arterial occlusive disease. J Am Col Cardiol 1998 Nov;32(5):1336-44
34. Maxwell AJ, Anderson BE Cooke JP. Nutritional therapy for peripheral artery disease. Vasc Med 2000;5(1):11-19
35. Hiatt WR. New treatment options in intermittent claudication: the US experience. Int J Clin Pract Suppl 2001 Apr;(119):20-27
36. Creager MA. Medical management of peripheral artery disease. Cardiol Rev 2001 Jul-Aug;9(4):238-45
37. Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE. A randomized double- blind study of oral L-arginine for treatment of interstitial cystitis. J Urol 1999 Feb; 161(2):558-65
38. Cartledge JJ, Davies AM, Eardley I. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. BJU Int 2000 Mar; 85(4):421-6
39. Sisic D, Francishetti A, Frolich ED. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive and normal rats. Hypertension 1999 Jan;33(1 Pt 2):451-5
40. Higashi Y, et al. Effects of L-arginine infusion on renal hemodynamics in patients with mild hypertension. Hypertension1995;25(4):898-902
41. Hishikawa K, et al. Role of L-arginine-nitric oxide pathway in hypertension. J Hypertens 1993 Jun; 11(6):639-45
42. . Dominiczak AF, Bohr DF. Nitric oxide and its’ putative role in hypertension. Hypertension 1995;25(6):1202-11
43. Nakaki T, et al. L-arginine induced hypotension. Lancet 1990Oct 20; 336(8721):1016-7
44. Braga M, Gianotti L Raedelli G, et al. Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. Arch Surg 1999 Apr;134(4):428-33
45. Ghigo E, Aimaretti G, Cornelli G, et al. Diagnosis of GH deficiency in adults. Growth Hormone IGF Res 1998 Feb;8 Suppl A:55-8
46. Wideman L Weltman JY, Patrie JY, et al. Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise. Am J Physiol Regul Integr Comp Physiol 2000 Oct;279(4):R1467-77
47. Gianotti L, Macario M, Lanfranco F, et al. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. J Clin Endocrinol Metab 2000 Oct;85(10):3604-8
48. Mauras N, Walton P, Nicar M, et al. Growth hormone stimulation testing in both short and normal statured children. Pediatr Res 2000 Nov;48(5):579-80
49. Ghigo E, Arvat E, Gianotti L, et al. Hypothalamic growth hormone-insulin-like growth facto-1 axis across the human life span. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1493-502
50. Korbonits M, Kaltsas G, Perry LA, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999 Jul;84(7):2489-95
51. Wallace AW, Ratcliffe MB, Galindez D, Kong JS. L-arginine infusion dilates coronary vasculature in patients undergoing coronary bypass surgery Aenesthesiology 1999 Jun;90(6):1577-8
52. Chen J, Wollman Y, Chernichovsky T, et al. Effect of high dose nitric oxide donor L-arginine in men with organic erectile dysfunction. BJU Int 1999 Feb;83(3):269-73
53. Kobayashi N, Nakamura M, Hiramori K. Effects of infusion of L-arginine on exercise-induced myocardial ischemic changes and capacity to exercise of patients with stable angina pectoris. Coron Artery Dis 1999 Jul;10(5):321-6
54. Bednarz B, Wolk R, Chamiec T, et al. Effects of oral L-arginine supplementation on exercised induced QT dispersion and exercise tolerance in stable angina pectoris.Int J Cardiol 2000 Sep 15; 75(2-3): 205-10
55. De Nicola L, Bellizzi V, Minutolo R, et al. Randomized, double-blind, placebo controlled study of arginine supplementation in chronic renal failure. Kidney Int 1999 Aug;56(2):674-84
56. Watanabe G, Tomiyama H, Doba N. Effects of oral L-arginine on renal function in patients with heart failure. J Hypertens 2000 Feb;18(2):229-34
57. Kelly BS, Alexander JW Dreyer D, et al. Oral arginine improves blood pressure in renal transplant and hemodialysis patients. J Parenter Enteral Nutr 2001 Jul-Aug; 25(4): 194-202
58. Efron DT, Barbul A. Arginine and nutrition in renal disease. J Ren Nutr 1999 Jul;9(3):142-4
59. . Reckelhoff JF, et al. Long-term dietary supplementation with L-arginine prevents age related reduction in renal function. Am J Physiol 1997 Jun; 272(6 Pt 2):1768-74
60. Reyes AA, Purkerson ML, Karl L, Klahr S. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992 Aug; 20(2):454-5
61. Bradley SJ, Kingwell BA, McConell GK. Nitric oxide synthase inhibition reduces leg glucose uptake but not blood flow during dynamic exercise in humans. Diabetes 1999 Sep; 48(9):1815-21
62. De Gouw HW, Verbruggen MB, Twiss IM, Sterk PJ. Effect of oral L-arginine on airway hyper-responsiveness to histamine in asthma. Thorax 1999 Nov;54(11):1033-5
63. De Gouw HW, Marshall-Partridge SJ, et al. Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects. J Appl Physiol 2001 Feb;90(2):586-92
64. Boer J, et al. Role of L-arginine deficiency of nitric oxide and airway hyperreactivity after allergen-induced early asthmatic reaction in guinea-pigs. Br J Pharmacol 1999 Nov;128(5):1114-20
65. Blease K, Kunkel SL, Hogaboam CM. Acute inhibition of nitric oxide exacerbates airway hyperresponsiveness, eosinophilia and C-C chemokine generation in a murinemodel of fungal asthma. Inflamm Res 2000 Jun; 49(6):297-304
66. Du J, Cui D, Tian D. [ The role of nitric oxide in the pathogenesis of asthma.] [ Full text in Chinese] Zhonghua Jie He He Hu Xi Za Zhi 1997 Jun;20(3):153-6
67. Gionotti L, Braga M, Fortis C, et al. A prospective, randomized clinical trial on perioperative feeding with an arginine-, omega-3 fatty acid-, and RNA enriched enteral diet: effect on host response and nutritional status. J Parenter Enteral Nutr1999 Nov- Dec;23(6):314-20
68. Efron D, Barbul A. Role of arginine in immunonutrition. J Gastroentol 2000;35 Suppl 12:20-3
69. Lewis B, Langkamp-Henken B. Arginine enhances in vivo immune responses in young, adult and aged mice. J Nutri 2000;130(7):1827-30
70. Mannick JB, et al. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994 Dec 30;79(7):1137-46
71. Ochoa JB, et al. Effects of L-arginine on the proliferation of T-lymphocyte subpopulations. J Parenter Enteral Nutr 2001 Jan-Feb;25(1):23-9
72. di Luigi L, Guidetti L, Pigozzi F, et al. Acute amino acid supplementation enhances pituitary responsiveness in athletes. Med Sci Sports Exerc 1999 Dec;31(12):1748-54
73. Lawecki J et al. Serum insulin, pancreatic glucagons and growth hormone levels in response to intravenous infusion of L-arginine in patients with recently detected juvenile diabetes. Pol Med Sci Hist Bull 1976 Apr-Jun;15(2):177-82
74. Valcenti S, et al Biphasic effect of nitric oxide on testosterone and cyclic GMP productionby purified rat Leydig cells cultured in vivo. Int J Androl 1999 Oct; 22(5):336- 41
75. Stevens BR, Godfrey MD, Kaminski TW, Braith RW. High intensity dynamic human muscle performance enhanced by a metabolic intervention. Med Sci Sports Exerc 2000 Dec;32(12):2102-8
76. Piatti PM, Monti LD, Valsecchi G, et al. Long term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetes. Diabetes Care 2001 MAY;24(5):875-80
77. Giugliana D, et al. Vascular effects of acute hyperglycemia are reversed by L- arginine. Circulation 1997; 95(7):1783-90
78. Mohan IK, Cas UN. Effects of L-arginine-nitric oxide system on chemical induced diabetes mellitus. Free Radic Biol Med 1998 Nov 1;25(7):757-65
79. Mendez JD, Balderas F. Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in Diabetic rats. Biochemie 2001 May;83(5):453-8
80. Kaposzta Z, et al. L-arginine and S-nitroglutathione reduce embolization in Humans. Circulation 2001;103(19):2371-75
81. Bode-Boger SM, Boger RH, et al. Differential inhibition of human platelet aggregation and thromboxane A 2 formation by L-arginine in vivo and in vitro. Arch Pharmacol 1998; 357:143-150
82. . Wolf A, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997 Mar 1; 29(3):479
83. Le Yorneau T, Van Belle E, Corseaux D, et al . Role of nitric oxide in re-stenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit. J Am CollCardiol 1999 Mar;33(3):876-82
84. Janero DR, Ewing JF. Nitric Oxide and Postangioplasty re-stenosis: Pathologicalcorrelates and therapeutic potential. Free Radic Biol Med 2000 Dec 15;29(12):1199-221
85. Severin P, et al. Local intramural delivery of l-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 1997;95(7):1863-9
86. Thomas S, Ramachandran A, Patra S, et al. Nitric oxide protects the intestine from the damage induced by laparotomy and gut manipulation. J Surg Res 2001 Jul;99(1):25-32
87. Sahin AS, Atalik KE, Gunel E, Dogan N. Nonadrenergic, noncholinergic responses of the human colon smooth muscle and the role of K+channels in these responses.. Methods Find Exp Clin Pharmacol 2001 Jan-Feb;23(1):13-7
88. Fini M, et al. Effect of l-lysine and L-arginine on primary osteoblast cultures from normal and osteopenic rats Biomed Pharmacother 2001 May;55(4):213-21
89. Aikawa K, Yokota T, et al. Endogenous nitric oxide-mediated relaxation and nitrinergic innervation in the rabbit prostate: the change with aging. Prostate 2001 Jun 15;48(1):40-6
90. Suematsu Y, Ohtsuka T, et al. L-Arginine given after ischemic preconditioning can enhance cardioprotection in isolated rat hearts. Eur J Cardiothorac Surg 2001, Jun;19(6):873-9
91. Koglin J. Pathogenetic mechanisms of cardiac allograft vasculopathy-impact of nitric oxide. Z Kardiol 2000;89 Suppl 9:IX/24-7
92. Kown MH, Van Der Steenhoven T, Uemura S, et al. L-Arginine polymer mediated inhibition of graft coronary artery disease after cardiac transplantation. Transplantation 2001 June 15;71(11):1542-8
93. Freedman RR, Girgis R, Mayers MD. Acute effect of nitric oxide on Raynaud’s phenomenon in scleroderma. Lancet 1999 Aug 28:354;739
94. Morric CR, Kuypers FA, et al. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Ped Hemat/Onc 2000 Nov-Dec;22(6):515-20
95. Kumar CA, Das UN. Lipid peroxides, antioxidants and nitric oxide in patients with pre-eclampsia and essential hypertension. Med Sci Monitor 2000 Sep-Oct;6(5):901-7
96. Nagaya N, Uematsu M, et al. Short term oral administration of l-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Resp Crit Care Med 2001 April;163(4):887-91
97. Barbul A, et al. Arginine enhances wound healing and lymphocyte immune responsesin humans. Surgery 1990 Aug;108(2):331-6; discussion 336-7
98. Kirk SJ, et al Arginine stimulates wound healing and immune function in elderly humans. Surgery 1993 Aug;114(2):155-9; discussion 160
99. De-Souza DA, Greene LJ. Pharmacological nutrition after burn injury. J of Nutri 1998 May;128(5):797-803
100. Blum A, Cannon RO, Costello R, et al. Endocrine and lipid effects of oral L- arginine treatment in healthy postmenopausal women. J Lab Clin Med 2000 Mar;135(3):231-7
101. .Ohta Y, Nishida K., Protective effect of l-arginine against stress-induced gastric mucosal lesions in rats and its relation to nitric acid-mediated inhibition of neutrophil infiltration. Pharmacal Res 2001 Jun;43(6):535-41
102. Khattab MM, Gad MZ, Abdallah D. Protective role of nitric oxide in indomethacin- induced gastric ulceration by a mechanism independent of gastric acid secretion. Pharmacol Res 2001 May;43(5):463-7
103. Calver A, Collier J, Vallance P. Dilator actions of arginine in human peripheral vasculature. Clin Sci 1991 Nov;81(5):695-700
104. Bode-Boger SM, Boger RH,et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996 Jan 1; 93(1):85-90
105. Vallet B. Microthrombosis in sepsis. Minerva Anestesiol 2001 Apr;67(4):298-301.
106. Hambrecht R, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000 Mar 1; 35(3):706-13
107. Heys SD, et al. Dietary supplementation with L-arginine: Modulation of tumor infiltrating lymphocytes in patients with colo-rectal cancer. Br J Surg 1997 Feb;84(2):238-41
108. Brittenden J, et al. Dietary supplementation with L-arginine in patients with breast cancer(> 4cm.) receiving multi-modality treatment: report of a feasibility study. Br J Cancer 1994 May;69(5):918-21
109. McCarty MF. Vascular nitric oxide, sex hormone replacement, and fish oil may help to prevent Alzheimer’s disease by suppressing synthesis of acute-phase cytokines.Med Hypotheses 1999 Nov;53(3):369-74
110. Tarkowski E, et al. Intrathecal release of nitric oxide in Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 2000 Nov- Dec;11(6):322-6
111. de la Torre JC, Stefano GB. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev 2000 Dec;34(3):119-36
112. Kuiper MA, et al. Decrease cerebrospinal fluid nitrate levels in Parkinson’s disease, Alzheimer’s disease and multiple system atrophy patients. J Neurol Sci 1994 Jan; 121(1):46-9
113. Pautler EL. The possible role and treatment of deficient microcirculation regulation in age-associated memory impairment. Med Hypotheses 1994 Jun;42(6):363-6
114. Pandhi P, Balakrishnan S. Cognitive dysfunction induced by phenytoin and valproate in rats: effect of nitric oxide. Indian J Physiol Pharmacol 1999 Jul; 43(3):378- 82
115. Pendergast MA, et al. Nitric oxide synthase inhibition impairs delayed recall in mature monkeys. Pharmacol Biochem Behav 1997 Jan;56(1):81-7
116. Fideieff HL,et al. Reproducibility and safety of the arginine test in normal adults.Medicina (B Aires) 1999; 59(3):249-53
117. Fagan JM, et al. L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun 1999 Jan 8; 254(1):100-3
118. Nitric oxide and pulmonary hypertension. Coron Artery Dis 1999 Jul; 10(5):287

END OF REFERENCES